ResMed (RMD) General Counsel Michael J Rider Sells $102K of Stock

By TradeTexts Research Desk Oct 26, 2026, 4:01 PM EDT

Key Points

Michael J Rider, ResMed's Global General Counsel, sold 400 shares at $255.00 each, totaling $102,000.
The stock closed at $252.86 on the day of the sale and recently traded around $253.24, about equal to that closing price.
Rider's sale reduces his holdings to 12,318 shares, a decrease of 3.15%.

Since the trade, $RMD is up 0.1% to date (from the $252.86 close on Oct 23, 2026).

Get ResMed text alerts

We text you when insiders, Congress, analysts or big funds move on $RMD.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated ResMed Inc. alert may contain errors. Disclosures

Michael J Rider, the Global General Counsel of ResMed Inc. (NYSE: RMD), sold 400 shares on October 23, 2026, for a total of $102,000. This transaction was reported in a Form 4 filing with the SEC. The shares were sold at a price of $255.00 each, slightly above the stock's closing price of $252.86 on the same day.

RMD ResMed Inc.

$253.24 +4.29% year to date

Daily close · Oct 26, 2026

What Changed in Rider's ResMed Position

Rider's sale reduced his ownership by about 3.15%, leaving him with 12,318 shares after the transaction. This marks a planned sale, indicating it was likely part of a strategy rather than an immediate response to market conditions.

Other Institutional Activity in ResMed

Several other institutional investors have made moves regarding ResMed recently. Bank Of New York Mellon Corporation trimmed its holdings by 728,006 shares, now owning 4,197,610 shares valued at approximately $1.06 billion. In contrast, First Trust Advisors LP increased its position by 740,907 shares, bringing its total to 2,278,696 shares worth about $577 million.

ResMed Inc. Stock Up 0.1%

As of October 26, 2026, ResMed shares traded recently around $253.24, which is about equal to the closing price on the day of Rider's sale. The stock is currently above its 50-day moving average by 10.3% and its 200-day moving average by 12.5%. However, it remains about 8.8% below its 52-week high of $277.67.

Recent Earnings

For the trailing twelve months, ResMed reported revenue of approximately $5.65 billion, with an earnings per share of $10.43. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at ResMed Inc.

Since June, several insiders have sold shares of ResMed. Peter Craig Farrell, a Director, sold 8,000 shares on August 5, 2026, at an average price of $225.00. CEO Michael J Farrell also sold shares on multiple occasions, with the most recent sale being 4,991 shares at $226.33 on October 7, 2026.

Analysts Set New Price Targets

Analysts have mixed views on ResMed's future. On August 7, 2026, RBC Capital maintained its rating at Sector Perform with a price target of $244.00. Keybanc upgraded its rating to Overweight with a target of $267.00 on August 31, 2026. The consensus among analysts is currently a buy with a mean price target of $251.52.

About ResMed

ResMed Inc. specializes in digital health and cloud-connected medical devices, focusing on sleep and breathing health as well as residential care software. Its innovative products aim to improve the quality of life for patients with respiratory conditions. The company's strong performance is reflected in its solid revenue growth and ongoing demand for its healthcare solutions.

Bottom Line

Investors should keep an eye on ResMed's upcoming earnings report on October 29, 2026, for insights into its financial health. Additionally, further insider trading activity may provide context for future stock performance.